Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi)
- Disease/Condition
- Rectal Cancer
- Drug/Device/Intervention
- Camrelizumab ＋Immunotherapy
- Study type
- Interventional
- Intervention type
- drug
- Primary sponsor
- Peking University Cancer Hospital & Institute
- Location
- Beijing, China
- Phase
- Phase 3
- Start date
- Mar 29, 2023
- End date
- Oct 01, 2029
- Enrollment
- 472 participants
The PCR rate between total neoadjuvant treatment ±immunotherapy
The goal of this clinical trial is to compare the PCR rate between Total Neoadjuvant
 Treatment ±Immunotherapy in high risk locally advanced rectal cancer. The main questions it
 aims to answer are:
 
 - The PCR rate between the two groups
 
 - The 3years DFS between the two groups
 
 - Chemoradiotherapy and immunotherapy toxicity
 
 - Postoperative complications Participants will receive total neoadjuvant treatment
 ±immunotherapy followed by surgery.
 
 Researchers will compare neoadjuvant treatment ±immunotherapy to see the PCR rate.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06229041
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06229041 through Pure Global AI's free database. This Phase 3 trial is sponsored by Peking University Cancer Hospital & Institute and is currently Recruiting. The study focuses on Rectal Cancer. Target enrollment is 472 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.